In conclusion, the current study demonstrated differences in pre-treatment levels of S-EGFR, S-EGF, S-HBEGF, S-AREG, and S-TGFα s in early-stage breast cancer patients as compared to a healthy control group. The gene discussed is EGFR; the disease is breast carcinoma.